Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Operating Officer | April 10, 2023 | April 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date April 10, 2023 · Filed April 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 175,361 |
Ending reported balance
After 2023-04-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-10 · Sale · Disposed 817 · Balance 177,669 F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Row 2 · 2023-04-11 · Sale · Disposed 2,308 · Balance 175,361 F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 11, 2023 Filed Apr 12, 2023 18:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,308 | $8.63 | $19,918.04 |
DisclosureSEC source: 0001062993-23-009085 · form4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,361 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 18:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 817 | $8.50 | $6,944.50 |
DisclosureSEC source: 0001062993-23-009085 · form4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,669 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 20:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 17,155 | $8.60 | $147,533.00 |
DisclosureSEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 3 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,486 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.245 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 133,033 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006327 · form4.xml · derivative · entry 4 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,033 Underlying: Common Stock · 133,033 shares Expires 2033-03-06 F4 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,529 | $8.57 | $55,953.53 |
DisclosureSEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,641 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 20:03 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 88,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006327 · form4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,170 Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,130 | $8.58 | $18,275.40 |
DisclosureSEC source: 0001209191-23-003052 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,518 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 995 | $8.50 | $8,457.50 |
DisclosureSEC source: 0001209191-23-003052 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,648 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| October 10, 2022 Filed Oct 11, 2022 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,284 | $7.13 | $16,284.92 |
DisclosureSEC source: 0001209191-22-053372 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,643 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 18:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 841 | $7.61 | $6,400.01 |
DisclosureSEC source: 0001209191-22-053372 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,927 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 08, 2022 Filed Jul 8, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,300 | $10.47 | $24,081.00 |
DisclosureSEC source: 0001209191-22-041730 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,768 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 825 | $9.53 | $7,862.25 |
DisclosureSEC source: 0001209191-22-041730 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,068 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 831 | $13.17 | $10,944.27 |
DisclosureSEC source: 0001209191-22-023916 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,893 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,244 | $12.01 | $14,940.44 |
DisclosureSEC source: 0001209191-22-017392 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,724 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 185,338 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017392 · doc4.xml · derivative · entry 3 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,338 Underlying: Common Stock · 185,338 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 74,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017392 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,968 Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,021 | $23.32 | $23,809.72 |
DisclosureSEC source: 0001209191-22-002766 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,833 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| October 08, 2021 Filed Oct 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,801 | $33.67 | $60,639.67 |
DisclosureSEC source: 0001209191-21-060116 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,854 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| October 07, 2021 Filed Oct 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,324 | $32.47 | $42,990.28 |
DisclosureSEC source: 0001209191-21-060116 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,655 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| July 08, 2021 Filed Jul 8, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,254 | $36.30 | $81,820.20 |
DisclosureSEC source: 0001209191-21-046083 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,979 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.99 to 36.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 871 | $39.42 | $34,334.82 |
DisclosureSEC source: 0001209191-21-046083 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,233 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,583 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · derivative · entry 3 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,417 Underlying: Common Stock · 14,583 shares Expires 2030-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on April 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 14,583 | $40.00 | $583,320.00 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · nonDerivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,104 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,583 | $28.10 | $409,782.30 |
DisclosureSEC source: 0001209191-21-042290 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,914 | $38.77 | $345,595.78 |
DisclosureSEC source: 0001209191-21-041088 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,104 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.31 to 39.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 15:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,586 | $42.34 | $151,831.24 |
DisclosureSEC source: 0001209191-21-026200 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,018 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 51,511 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-21-018741 · doc4.xml · derivative · entry 2 ADAMS R MARK · CIK 0001808905 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,511 Underlying: Common Stock · 51,511 shares Expires 2021-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 19:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 20,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018741 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,604 Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $28.10 | $0.00 |
DisclosureSEC source: 0001209191-20-023973 · doc4.xml · derivative · entry 2 ADAMS R MARK · CIK 0001808905 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-06 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on April 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 20:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023973 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.